Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer

(2021) Jie Wang et al.   JAMA Oncology

Tislelizumab Plus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (RATIONALE 304): A Randomized Phase 3 Trial

(2021) Shun Lu et al.   Journal of Thoracic Oncology

Sintilimab Plus Platinum and Gemcitabine as First-Line Treatment for Advanced or Metastatic Squamous NSCLC: Results From a Randomized, Double-Blind, Phase 3 Trial (ORIENT-12)

(2021) Caicun Zhou et al.   Journal of Thoracic Oncology

PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study

(2021) M. Johnson et al.   Journal of Thoracic Oncology

Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

(2020) Robert Jotte et al.   Journal of Thoracic Oncology

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11)

(2020) Yunpeng Yang et al.   Journal of Thoracic Oncology

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial

(2020) Makoto Nishio et al.   Journal of Thoracic Oncology

Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial

(2020) Caicun Zhou et al.   Lancet Respiratory Medicine

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis

(2019) Urania Dafni et al.   LUNG CANCER

Abandoning the Notion of Non-Small Cell Lung Cancer

(2019) Valeria Relli et al.   TRENDS IN MOLECULAR MEDICINE

Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials

(2019) Yucai Wang et al.   JAMA Oncology

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

(2018) Mark A. Socinski et al.   Journal of Thoracic Oncology

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Microenvironment Differences between Squamous and Non-squamous Non-small Cell Lung Cancer and Their Influence on the Prognosis

(2018) Xiangjiao Meng et al.   Clinical Lung Cancer

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Estimating Survival in Patients With Lung Cancer and Brain Metastases

(2017) Paul W. Sperduto et al.   JAMA Oncology

Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014

(2015) Daniel Morgensztern et al.   Journal of Thoracic Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER